Industry Stakeholders Debate Ways To Make Medicare Price Negotiation Policies Palatable
Executive Summary
Pharma leaders and stakeholders discussed industry priorities related to the implementation of the Inflation Reduction Act during the BIO CEO and Investor Conference.
You may also be interested in...
Medicare Price Negotiation: Special Treatment For ‘Novel Technologies’ On PhRMA’s Advocacy Agenda
Novartis CEO Vasant Narasimhan, PhRMA's incoming board chair, says in an interview that the brand drug association has a slate of issues to pursue as it works to shape the implementation of the Medicare price negotiation program in the name of preserving innovation.
In Medicare Drug Price Negotiations, Industry Sees Drawbacks And Silver Linings
Industry leaders are concerned about the outlook for small molecule drugs in particular, but execs at the J.P. Morgan Healthcare Conference were also optimistic there could be chances to shape the implementation of certain policies.
Medicare Price Negotiation: Sponsors Will Have A Say, But Likely Not Sway As Timetable Comes Into Focus
CMS details when it will release information and receive public comments in the lead-up to publishing the initial list of drugs to be negotiated this fall.